Tradestie Institutional Equity Comparison Engine

BMY vs SGP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMY Overall Edge

BMY Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bristol-Myers Squibb Co. (BMY) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BMY trades at 9.4x Forward P/E with 32.4% operating margin (+6.9% YoY revenue) versus SGP at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, BMY sits in CONSOLIDATION (31st %ile IV; Dealer Gamma Walls on Pro) against SGP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner BMY
BMY 9.4x vs SGP N/M Fwd P/E
Growth & Margin Winner BMY
Op Margin 32.4% vs N/A ยท YoY +6.9% vs N/A
Momentum & Technical Winner BMY
1Y +29.4% vs +22.1% ยท 52W Pos 76% vs 66%
Options & Structure Winner BMY
CONSOLIDATION (31st %ile IV) vs UNCLASSIFIED (N/A IV)
BMY NYSE
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
$62.93
-0.79% 1D
Market Cap $129.7B
1M Return +5.32%
1Y Return +29.41%
Forward P/E 9.4x
Unified AI Score
53.5 / 100 HOLD
Tech 50.0 Fund 58.0 Flow 70.0 Mom 50.0
SGP US Equity
SGP
Institutional Equity
$32.24
-1.95% 1D
Market Cap N/A
1M Return +34.33%
1Y Return +22.12%
Forward P/E N/M
Unified AI Score
39.3 / 100 SELL
Tech 15.0 Fund 45.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BMY +29.41% SGP +22.12% Spread: +20.6 pp (SGP Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BMY TTM Op. Margin: 32.4% SGP TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMY vs SGP. Trailing 12-month operating profitability (BMY 32.4% vs SGP N/A) and valuation multiples (BMY 9.4x vs SGP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BMY (10) vs SGP (0)
Institutional Metric BMY SGP Criterion Row Winner
Market Capitalization Scale $129.7B N/A Larger Scale BMY
Trailing P/E Ratio Valuation 14.1x N/M Lower Multiple BMY
Forward P/E Ratio Valuation 9.4x N/M Lower Multiple BMY
Revenue Growth (YoY) Growth +6.9% N/A Higher Growth BMY
Operating Margin (TTM) Profitability 32.4% N/A Higher Margin BMY
Net Profit Margin Profitability 18.5% N/A Higher Margin BMY
Return on Equity (ROE) Capital Efficiency 44.0% N/A Higher ROE BMY
52-Week Range Position Momentum 76% ($45โ€“$69) 66% ($17โ€“$40) Stronger Trend BMY
Beta / 30D Volatility Risk Regime 0.17ฮฒ ยท 31% Vol 1.38ฮฒ ยท 70% Vol Lower Realized Risk BMY
Unified Institutional Score Composite Signal 53.5 / 100 (HOLD) 39.3 / 100 (SELL) Higher Composite BMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BMY vs SGP Buy Guide
BMY CONSOLIDATION
51d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 31st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live BMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SGP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SGP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BMY nor SGP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.